TrialSignal
Clinical trial intelligence report
TRANSLATIONAL THERAPY IN PATIENTS WITH OSTEOGENESIS IMPERFECTA - A PILOT TRIAL ON TREATMENT WITH THE RANKL-ANTIBODY DENOSUMAB
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01799798
Status
COMPLETED
Phase
Phase 2
Sponsor
University of Cologne
Executive brief
Investment-Ready Snapshot
This pilot trial evaluated the efficacy of Denosumab, a RANKL antibody, in treating children aged 5-10 with Osteogenesis Imperfecta caused by COL1A1 or COL1A2 mutations. The study aimed to assess changes in bone mineral density (BMD) after 36 weeks of treatment.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01799798
Indication
Osteogenesis Imperfecta
Modality
monoclonal antibody
Target
Osteogenesis Imperfecta
Intervention
Denosumab
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.